Polysubstituted indan-1-ol systems for the prophylaxis or treatment of obesity
AssigneeAventis Pharma Deutschland GmbH
InventorsGerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
Life of this patent
Estimating the term…
Loading patent…
AssigneeAventis Pharma Deutschland GmbH
InventorsGerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
Estimating the term…
Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed: Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.
A compound of the formula I:
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Sulfur, selenium, or tellurium compounds, e.g. thiols: sulfides; Sulfoxides; Sulfones
Having aromatic rings , e.g. ketamine, nortriptyline: arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
Having oxygen as the only ring hetero atom, e.g. fungichromin: lactones
1,3-Diazoles: condensed with carbocyclic rings, e.g. benzimidazoles
Term ended 29 Aug 2022 (estimated)
1. Field of the Invention
The invention relates to polysubstituted indan-1-ol compounds and their physiologically acceptable salts and physiologically functional derivatives for the prophylaxis or treatment of obesity.
2. Description of the Related Art
Soft gelatin capsules, comprising 100 mg of active compound per capsule:
per capsule Active compound 100 mg Triglyceride mixture fractionated from coconut butter 400 mg Capsule contents 500 mg
Emulsion, comprising 60 mg of active compound per 5 ml: